Founded with a mission to innovate non-invasive ocular imaging, OcuSciences is a medical diagnostic device company specializing in the early detection and monitoring of retinal metabolic dysfunction, particularly related to diabetes. The company’s flagship product, the OcuMet Beacon, utilizes the proprietary MitoPhor™ technology to provide rapid and automated assessments of ocular health. This technology aids ophthalmologists and optometrists in diagnosing and managing eye diseases efficiently.
OcuSciences has garnered attention for its cutting-edge approach to ocular health, attracting notable investors and affiliations within the medical and technological communities. The company's achievements include the successful development and deployment of the OcuMet Beacon, which has significantly impacted the early diagnosis and treatment of diabetes-related eye conditions. Through its innovative solutions, OcuSciences continues to enhance the quality of eye care and improve patient outcomes globally.
